INFOGRAPHIC: 72 US IPOs gross $5.7bn in 2014; values rising in 2015
This article was originally published in Scrip
In 2014, 72 biotechnology firms that develop drugs, biologics and gene, stem or cell therapies grossed $5.7bn from initial public offerings in the US with most companies ending the year with stock values well above their IPO price – and values have risen higher in 2015.
You may also be interested in...
Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter
Venture capital investment in biopharmaceutical firms for the first half of 2017 show that this year is on track to exceed 2016 levels. Recent financings include two $50m Series C rounds for two different companies developing later-stage drugs for itching: Trevi and Menlo Therapeutics.
Ionis Invests For The Future In New Technologies, Manufacturing Innovation
Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.